PREvention of Intrauterine Adhesion After Hysteroscopic Surgery With Novel deGradable Film
- Conditions
- Intrauterine Adhesion
- Interventions
- Device: Womed Leaf
- Registration Number
- NCT04381728
- Lead Sponsor
- Womed
- Brief Summary
Intrauterine adhesions (IUA) are the major long-term complication of intrauterine procedures and are associated with pelvic pain, menstrual disorders, obstetrical complication and infertility.
Womed Leaf is a medical device specifically designed for intrauterine use that prevents intra-uterine adhesions. It is a film that acts as a mechanical barrier to keep uterus walls separated during healing. It is then naturally discharged through the cervix and vagina in less than 30 days.
The PREG1 clinical investigation is designed to evaluate Womed Leaf safety under clinical conditions, in women scheduled for a hysteroscopic myomectomy as well as its efficacy.
- Detailed Description
Intrauterine adhesions (IUA) are defined as "fibrous strings at opposing walls of the uterus and/or cervix leading to partial or complete obliteration of the cavity". IUAs are the major long-term complication of intrauterine procedures and are associated with pelvic pain, menstrual disorders, obstetrical complications and infertility.
Womed Leaf™ is a sterile, degradable polymer film specifically design for intrauterine use. It is inserter in the uterus like an intrauterine device. Once released it will self-deploy into the uterine cavity to form a mechanical barrier keeping uterus walls separated during healing, for several days, thus preventing the formation or recurrence of intrauterine adhesions. It is degraded and discharged naturally through the cervix and vagina in less than 30 days.
The PREG1 clinical investigation is a prospective multicenter, single arm study, designed to evaluate Womed Leaf safety under clinical conditions, in women scheduled for a hysteroscopic myomectomy as well as its efficacy in preventing IUA at second look hysteroscopy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 23
- Women ≥ 40 years AND no childbearing wish, OR history of permanent sterilization;
- Subject scheduled for hysteroscopic myomectomy for one or more myoma(s) where one myoma is at least 10 mm in size (≥10mm) as estimated by pre-operative ultrasound measurement of the largest diameter,
- Hysterometry prior to device insertion ≥ 6cm and ≤ 9cm.
- Subjects who are willing to provide a written informed consent as approved by the applicable Ethics Committee prior to participating in this clinical investigation.
- Subjects who can comply with the study follow-up or other study requirements
Pre-operative exclusion criteria:
- Current pregnancy
- Abnormal uterine cavity according to ESHRE classification I to VI, such as unicornis, bicornis, septate, duplex
- Known or suspected endometrial hyperplasia
- Medical history of cervical or endometrial cancer
- Active pelvic infection or medical history of pelvic peritonitis
- Intrauterine device in situ
- Known contraindication or hypersensitivity to PEO or PLA, and to medications such as aspirin....
- Concurrent medical condition with a life expectancy of less than 12 months
- Full endometrial ablation
Per-operative exclusion criteria:
- Adenomyosis
- Inflammation (endometritis)
- Abnormal uterine cavity
- Hysterometry < 6cm or >9cm
- Any complication during the intervention that is deemed to potentially interfere with the objective of the study by the investigator
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Womed Leaf Womed Leaf At the end of the hysteroscopic myomectomy, Womed Leaf is delivered in the uterus thanks to a 5mm diameter, flexible inserter. Then an endovaginal ultrasound will be performed to assess the positioning of the uterine film. Another ultrasound will be performed at 2 hours, prior to patient discharge in order to record images of the uterine film deployment. A second look hysteroscopy will performed at 4-8 weeks to evaluate the presence of intrauterine adhesion.
- Primary Outcome Measures
Name Time Method Safety (Adverse Events) 30 days The number and severity of polymer film related adverse event
Efficacy (Rate of Patient With no IUA) At second look hysteroscopy between 4 and 8 weeks Freedom from intrauterine adhesion
Efficacy (Intrauterine Adhesion Severity According to AFS Classification) At second look hysteroscopy between 4 and 8 weeks Severity of IUAs according to American Fertility Society (AFS) classification systems of adhesions.
Pronostic classification =\> Hysteroscopy score Stade I (mild) =\> 1-4 Stade II (moderate) =\> 5-8 Stade III (severe) =\> 9-12Efficacy (Intrauterine Adhesion Severity According to ESGE Classification) At second look hysteroscopy between 4 and 8 weeks Severity of IUAs according to European Society of Gynecological Endoscopy (ESGE) classification systems of adhesions.
I =\> Thin or filmy IUA easily ruptured by HSC sheath alone. Cornual areas normal II =\> Singular dense IUA connecting separate parts of the uterine cavity. Visualization of both tubal ostia possible. Cannot be ruptured by HSC sheath alone IIa =\> Occluding IUA only in the region of the internal cervical os. Upper uterine cavity normal III =\> Multiple dense IUA connecting separate parts of the uterine cavity. Unilateral obliteration of ostial areas of the tubes IV =\> Extensive dense IUA with (partial) occlusion of the uterine cavity. Both tubal ostial areas (partially) occluded Va =\> Extensive endometrial scarring and fibrosis in combination with grade I or grade II IUA with amenorrhea or pronounced hypomenorrhea Vb =\> Extensive endometrial scarring and fibrosis in combination with grade III or grade IV IUA with amenorrhea
- Secondary Outcome Measures
Name Time Method Adverse Events 30 days Number of adverse events (AE) at 30 days
Device Technical Success During operation: T=0 Defined as the rate of success of the following 2 steps : insertion and release
Device Manipulation During intervention: T=0 Device manipulation duration from insertion to withdrawal.
Womed Leaf Residuals At second look hysteroscopy: 4-8 weeks Presence of Womed Leaf residuals in the uterus
Womed Leaf Discharge Feedback : Time Interval in Days Between Surgery and Discharge At second look hysteroscopy: 4-8 weeks Uterine film discharge experience as recalled by subject using a survey to be asked to the patient
Womed Leaf Discharge Feedback Questionnaire (Polymer Tolerance Assessed on a Scale From 1 (no Discomfort) to 10 (Extremely Disturbing)) At second look hysteroscopy: 4-8 weeks Uterine film discharge experience as recalled by subject using a survey to be asked to the patient
Trial Locations
- Locations (6)
CHU Bicêtre (APHP)
🇫🇷Paris, France
CHU Nîmes
🇫🇷Nîmes, France
Bergman Clinics
🇳🇱Amsterdam, Netherlands
Zaans Medical Center
🇳🇱Amsterdam, Netherlands
Isala Zwolle
🇳🇱Zwolle, Netherlands
UZ Gent
🇧🇪Gent, Belgium